8:00 am Check In, Coffee & Light Breakfast
8:25 am Chair’s Opening Remarks
8:30 am Exploring the Clinical Development of the Fatty Acid Binding Protein 5 (FABP5) inhibitor ART26.12
9:00 am Out of the Shadow of Rimonabant? – The Re-emergence of Cannabinoid Medicines in Metabolic Dysfunction
Synopsis
- History of Cannabinoid Medicines in Metabolic Dysfunction
- Emergence of Peripherally Restricted CB1 Inverse Agonists
- Post GLP-1 / GIP Agonists – opportunities and limitations
Securing Strategic Investment: Building Investor Confidence to Drive Commercial Success in Cannabinoid Venture
9:30 am Panel Discussion: Investor Insights – Navigating the Funding Landscape for Cannabinoid Innovations
Synopsis
- Understanding key investor priorities: demonstrating clear pathways to commercial success and return on investment
- Presenting robust and relevant data that validates product efficacy, safety, and market potential to build credibility
- Exploring successful strategies for building long-term investor relationships and partnerships
10:15 am Morning Break & Networking
Navigating the Regulatory Landscape in Cannabinoid Drug Development to Accelerating the Path From R&D To the Clinic
11:00 am Accelerating Cannabinoid Drug Development: Navigating Global Regulatory Challenges for Faster Clinical Progress
Synopsis
- Gain clarity on how evolving international regulations and drug scheduling classifications impact clinical development timelines and trial design for cannabinoid therapeutics
- Discover proactive strategies to align regulatory planning with commercial goals, minimizing delays caused by inconsistent global frameworks
- Learn how to effectively navigate the regulatory distinctions between botanical and synthetic cannabinoids to ensure faster market entry
11:30 am Fireside Chat: Future-Proofing Your Regulatory Strategy – What’s Next for Cannabinoid Drug Policy?
Synopsis
- Forecast upcoming regulatory and political shifts globally, and how they are likely to shape cannabinoid drug approval pathways in the next 12 months
- Explore how companies are successfully managing international regulatory divergence to unlock broader market access for cannabinoid-based therapies
- Gain insights on how to communicate regulatory readiness to investors, partners, and stakeholders to build confidence in long-term development plans
12:00 pm Session Reserved For LCSW
12:10 pm Lunch & Networking Break
Optimizing Cannabinoid Drug Formulations: Enhancing Bioavailability, Integrating Combination Drugs & Ensuring Safety Drugs for Clinical Success
1:30 pm Utilizing Endocannabinoid Alterations to Target Different Populations for Treatment
Synopsis
- Exploring CB1 receptor availability, potentially contributing to heightened stress reactivity and increased risk of relapse in opioid-use disorder
- Establishing clinical relevance and explore endocannabinoid modulation as a treatment strategy
- Understanding what population is a better target to use in clinical trial for endocannabinoid modulation
2:00 pm Cannabinoid Combination Therapy Utilizing Corticosteroids & CBD
Synopsis
- Discussing preclinical and clinical data from equine studies demonstrating cartilage growth using CBD – corticosteroid combination therapeutics and insights into patient clinical trials for Crohn’s disease
- Exploring rational polypharmacy and the strategic drug combination methodologies aimed to reduce individual drug dosage whilst maintaining or enhancing therapeutic effect
- Analyzing dosing versus formulation and their significance on the pharmacokinetic and principles for combination drugs
NEW DATA
3:00 pm Utilizing Nanoencapsulated Cannabinoid Therapies for Chronic Treatment of Opiod Use Disorder
Synopsis
- Formulation to support the translation of cannabinoid – based therapies from acute to chronic therapeutic use
- Discussing the development of a combined CBD and naltrexone formulation designed to enhance efficacy and patient compliance in treating opioid use disorder
- Investigating the sustainability advantages of utilizing CO2 in the nanoencapsulation manufacturing process
NEW DATA
3:30 pm Afternoon Break
Novel Applications of Cannabinoid Drugs & Streamlining Translation from Preclinical to Clinical Trials for Cannabinoid Drugs to Maximise Resource Efficiency
4:00 pm Panel Discussion: Concurrent Modalities in Cannabinoid Therapeutics: Advances in Synthetic & Botanical Drug Development
Synopsis
- Navigating the differences in the regulatory landscape for botanical and synthetic drugs
- Discussing how research into both fields has contributed to the overall understanding of cannabinoid pharmacology
- Validating effectively scaling up in synthetic drug production versus maintaining API consistency in botanical drugs
4:30 pm Targeted Modifications to Cannabinoids to Propel Entry Into Clinical Trials
Synopsis
- Developing a structured framework for modifying certain parameters of cannabinoids e.g. CBD, to generate new molecules which can be IP protected
- Following criteria framework with well-understood molecules could lead to cannabinoids going into human studies faster than the current rate
- Prioritizing development efforts on different therapeutic areas including epilepsy & obesity